BELTSVILLE, MD--(Marketwire - July 27, 2010) - BioServe, a leading provider of genomic solutions and services to the Biotech industry, today announced a line of new molecular PCR tests for the detection of any and all commercialized GMOs (Genetically Modified Organisms) to a 0.1% limit of detection of the substance tested. In addition, the company today announced that its laboratories in India have received accreditation from the National Board of Testing and Calibration of Laboratories (NABL) for the detection of genetically modified materials in raw and processed foods.
"Genetically modified foods continue to proliferate, matched by increasing regulations of those GMOs by governing bodies around the world. In Europe, new regulations are responding to a public outcry for reliable information about GMOs in foods and the proper labeling of GMOs in food and feed. Our GMO screening tests along with our NABL accreditation provides our customers with reliable and accurate testing for GMOs in food," said Rama Modali, President, BioServe.
EU labeling laws now require that customers must be informed if 0.9% of a food or food product contains approved GMOs, or if the food contains 0.5% or more of a GMO that has been assessed as safe but not yet approved. Food producers and consumers want reliable, accurate GMO tests to ensure that food products are in compliance with these new laws. BioServe is one of few GMO testing laboratories in India with a comprehensive GMO testing to meet the needs of manufacturers and exporters of food and feed.
Modali added, "These tests for GMOs are the first of what will be a comprehensive portfolio of molecular tests for pathogens and healthcare diagnostics."
BioServe provides a comprehensive 'biomaterial to validated data' genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing BioServe's genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs. BioServe's services extend from nucleic acids processing, DNA synthesis, high throughput genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers. BioServe's Global BioRepository provides researchers with a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients from four continents.
For more information please visit www.bioserve.com or call 301-470-3362.